Digital pathology
Paige
Digital pathology AI applications for cancer pathology, including Paige Prostate.
Last updated: June 5, 2026
Back to directoryAiforia medical AI product profile
AI pathology platform with clinical suites for whole-slide image workflows, quantitative overlays, and pathologist review.
Digital pathology
Best fit
Labs evaluating AI-supported pathology workflows across breast, prostate, lung, colorectal, gastric, or lymph node use cases.
- Primary use case
- AI-assisted digital pathology suites for cancer diagnostics, quantitative image analysis, and case-level pathology reporting
- Audience
- Pathology labs, diagnostic networks, academic medical centers, and research pathology teams
- Risk level
- High
- Pricing signal
- Enterprise pricing; request current regional terms.
- Official sources
- 6 official sources
Compare within workflow: Digital pathology · comparison shortlist · source index
Regulatory, privacy, evidence, and workflow lens
Product-specific review. These product-specific signals summarize what the cited sources imply before treating Aiforia as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Match every Aiforia model to its CE-IVD, RUO, PSO, FDA, or local status; EU/EEA diagnostic claims for selected models should not be applied to all suites or markets. |
|---|---|
| Privacy | Verify cloud processing, hosting region, slide upload, scanner integration, retention, customer data-processing terms, access controls, audit logs, and whether public website privacy terms are separate from clinical deployment terms. |
| Evidence | Assess model-level performance by cancer type, tissue, stain, scanner, biomarker threshold, grade group, case prevalence, and pathologist review burden. |
| Workflow | Best used as pathologist-controlled whole-slide image support where overlays, quantitative scores, triage, case review, and final report responsibility remain explicit. |
Where Aiforia fits
Aiforia describes clinical pathology suites for whole-slide image analysis and notes that only certain clinical AI models and the Clinical Suite Viewer are CE-IVD marked for diagnostic use in the EU and EEA, with other markets limited to research or performance-study use.
Not for: Diagnostic deployment without model-specific regulatory review, scanner validation, and pathologist signout in the intended region.
What to verify before using Aiforia
- Which Aiforia clinical suite and AI models match the tissue, stain, and diagnostic workflow.
- CE-IVD, RUO, performance-study, FDA, or local regulatory status for every model in scope.
- Scanner, LIS, image-management, cloud, and reporting integration requirements.
- How pathologists review AI overlays, quantitative findings, exceptions, and final reports.
Source links
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.
- www.aiforia.com / aiforia-clinical-suite
- www.aiforia.com / breast-cancer-ai
- www.aiforia.com / prostate-cancer-ai
- www.aiforia.com / press-releases / aiforia-releases-a-new-ce-ivd-marked-ai-solution-for-gastric-cancer-diagnostics
- www.aiforia.com / privacy-policy
- www.aiforia.com / about-us
Related medical AI products
Digital pathology
PathAI
AI-enabled digital pathology platform with image management and algorithm access.
Digital pathology
Hologic Genius Digital Diagnostics
FDA-cleared digital cytology system combining volumetric imaging, Genius Cervical AI, image management, and cytologist or pathologist review.
Digital pathology
Ibex Medical Analytics
Clinical-grade AI pathology platform for cancer diagnostics and pathology workflow support.